Key facts
- InhaTarget Therapeutics’s last known valuation is $15.0M (Jan 2026).
- It has raised $11.1M; the latest was Early Stage VC ($4.3M) in Jan 2026.
- Notable investors include SambrInvest, Galephar Pharmaceutical Research, Laboratoires S.M.B., Matwin, Seido Capital — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for InhaTarget Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for InhaTarget Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About InhaTarget Therapeutics
Developer of an inhalable powdered medicine designed to improve lung cancer treatment. The company's product is a dry powder for inhalation that covers the gap between localized treatments and systemic treatments in lung cancer, enabling medical practitioners to have access to medicines that improve the treatment of severe and chronic respiratory diseases.
- Sector
- Healthcare
- HQ
- Gosselies, Belgium
- Founded
- 2018
- Employees
- 9
- Website
- inhatarget.com/
- Ownership
- Privately Held (backing)
InhaTarget Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in InhaTarget Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on InhaTarget Therapeutics in its N-PORT filings yet. We sweep new filings monthly.